source
- Gene-editing biotech Scribe Therapeutics files for Nasdaq IPOScribe Therapeutics, a California-based biotechnology startup developing genetic medicines for cardiometabolic disorders, announced plans to go public on the Nasdaq under the ticker SCTX. The comp…
- Novartis to acquire Myricx Bio for $1.1 billion to expand antibody-drug conjugate pipelineNovartis announced it will buy London-based Myricx Bio, agreeing to pay $1.1 billion upfront. The deal gives Novartis access to Myricx's novel payload technology - an N-myristoyltransferase inhibi…